
Corporate
Minerva Neurosciences Details Phase 3 Roluperidone Trial at LifeSci KOL Event — First Patient Expected Q2 2026
6h ago
You're signed outSign in or to get full access.
View earnings summary and analysis
View earnings summary and analysis
View earnings summary and analysis
Research analysts covering Minerva Neurosciences.